ASP Isotopes Inc.'s subsidiary, Renergen Limited, entered into a Second Amendment and Restatement Agreement with The Standard Bank of South Africa Limited on August 14, 2026. This agreement replaced the prior term loan facility, increasing the aggregate principal amount to ZAR 230,532,658.90 (approximately USD 14,212,864). The new secured loan matures on August 14, 2027, with interest accruing at a compounded reference rate plus 1.46%, resulting in an effective annual rate of 8.31%. Security includes a collateral account controlled by the lender and a pledge of 1,546,268 shares of ASP Isotopes common stock held by NTIGT Investments. A Put Option Agreement grants the lender the right to require the purchase of these pledged shares upon default. The company operates in the nuclear energy sector, focusing on isotope production.

ASP Isotopes Inc. announced on August 20, 2026, that Tetra4 Proprietary Limited has entered the commissioning phase of its Phase 1 liquid helium plant in South Africa. Commercial production is expected to commence in September 2026, with ramp-up to nameplate capacity targeted for the second half of 2026. Phase 1 is projected to produce approximately 70 Mcf/day of liquid helium and 2,500 GJ/day of LNG, potentially generating over $27 million in annualized revenues based on assumed pricing. The company has secured take-or-pay contracts for roughly 75% of Phase 1 LNG and 15% of its helium output. Construction of the significantly larger Phase 2 is planned to begin in late 2026, with up to $750 million in senior debt funding sought from the U.S. International Development Finance Corporation and Standard Bank of South Africa. ASP Isotopes operates an advanced materials company focused on developing technologies for the production of critical isotopes used in nuclear medicine, semiconductors, and energy.

ASP Isotopes Inc. announced on August 6, 2026, that Tetra4 Proprietary Limited, a subsidiary of Renergen Limited and developer of the Virginia Gas Project in South Africa, entered into a five-year take-or-pay contract to supply liquified natural gas (LNG) to a domestic food processor. The agreement is priced at greater than $16 per GJ and represents approximately 10% of Phase 1 nameplate capacity, bringing total contracted volumes for Phase 1 to approximately 75%. Phase 1 is targeted for completion in the third quarter of 2026, with commercial production expected to commence during that period. The project is anticipated to generate annualized revenues exceeding $27 million based on assumed pricing for LNG and liquid helium. ASP Isotopes operates an advanced materials company focused on developing technologies for the production of critical isotopes used in nuclear medicine, semiconductors, and nuclear energy.